What Is Visceral Fat and What Is a Good Visceral Fat Number?

What Exactly Is Visceral Fat?

Visceral fat is adipose tissue deposited inside the peritoneal cavity, tucked between and around your abdominal organs. It is not the soft layer you can grab at your waistline. That outer layer is subcutaneous fat, which sits between the skin and the abdominal muscle wall.

The distinction matters clinically because visceral fat behaves like an endocrine organ. It releases cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), as well as free fatty acids that drain directly into the portal vein and reach the liver first. This portal delivery is what makes visceral fat uniquely damaging compared with fat stored elsewhere in the body.

Why Visceral Fat Is Biologically Different from Subcutaneous Fat

Subcutaneous fat, stored under the skin of the abdomen, thighs, and buttocks, functions primarily as an energy reserve. It is relatively inert from an inflammatory standpoint.

Visceral fat, by contrast, is far more lipolytically active. Its cells turn over faster, release more free fatty acids per unit of mass, and are denser with macrophages. A 2019 analysis published in Obesity Reviews found that visceral adipose tissue produces roughly three times more inflammatory cytokines per gram than subcutaneous adipose tissue. [1]

The Organ-Specific Damage Visceral Fat Causes

The liver receives the first pass of all portal blood, so excess free fatty acids from visceral depots overwhelm hepatic lipid processing. This leads to hepatic insulin resistance, elevated triglycerides, and, over time, non-alcoholic fatty liver disease. The pancreas, sitting directly adjacent to mesenteric fat, faces localized inflammation that may impair beta-cell function. The cardiovascular system sees elevated LDL particle number and reduced HDL-cholesterol as downstream effects.

A 2020 study in the Journal of the American College of Cardiology (N=3,086) found that individuals in the highest quartile of visceral fat area had a 2.3-fold greater risk of major adverse cardiovascular events compared with those in the lowest quartile, independent of BMI. [2]

What Is a Good Visceral Fat Number?

The term "visceral fat number" appears most often in the context of consumer body-composition devices, such as Tanita bioelectrical impedance scales. These devices assign a visceral fat rating on a scale of 1 to 59. A rating of 1 to 12 is classified as healthy, 13 to 59 is classified as high, with some manufacturers further subdividing the high range into "high" (13 to 17) and "very high" (18 and above).

These ratings are estimates, not direct measurements. They correlate reasonably well with DEXA-derived visceral fat area in population studies, but individual error can be wide.

Clinical Cutoffs Used in Research and Practice

Research trials and clinical guidelines use visceral adipose tissue (VAT) area measured by imaging, not consumer scale ratings. Measured by CT or MRI cross-section at the L4-L5 vertebral level:

• A VAT area below 100 cm² is generally considered low risk.
• A VAT area of 100 to 160 cm² is considered moderately elevated.
• A VAT area above 160 cm² is associated with significantly increased metabolic and cardiovascular risk.

The International Diabetes Federation's 2006 consensus statement defined abdominal obesity as a waist circumference above 94 cm (37 inches) in European men and 80 cm (31.5 inches) in European women, with population-specific adjustments. [3] These waist thresholds serve as a practical proxy when imaging is not available.

DEXA Scanning as the Practical Clinical Standard

MRI and CT scanning are the gold-standard measurements, but radiation exposure from CT and cost from MRI limit routine use. DEXA scanning offers a reasonable middle ground. It separates fat mass into visceral adipose tissue and subcutaneous adipose tissue with acceptable accuracy, and many obesity medicine practices now include DEXA as a baseline body-composition assessment.

A 2016 review in Obesity confirmed that DEXA-derived VAT area correlates with CT-derived VAT at r=0.85 to 0.92 across multiple validation studies. [4] That level of correlation makes DEXA the preferred practical tool for tracking visceral fat changes over a treatment program.

HealthRX Clinical Framework: Choosing the Right Visceral Fat Measurement for Your Situation

| Clinical Situation | Recommended Method | Practical Notes | |---|---|---| | Research or bariatric surgery workup | CT or MRI at L4-L5 | Gold standard; CT carries radiation; MRI preferred for serial measures | | Obesity medicine clinic, metabolic program | DEXA whole-body scan | Best precision-to-cost ratio; tracks changes reliably | | Primary care or telehealth initial screen | Waist circumference | Simple, free, validated; pair with BMI for better prediction | | Home monitoring between clinical visits | Calibrated bioelectrical impedance scale (Tanita, InBody) | Useful for trends; avoid raw comparisons across devices |

Why Visceral Fat Levels Rise

Visceral fat accumulates when energy intake chronically exceeds expenditure, but the distribution of that fat into visceral versus subcutaneous depots is shaped by several additional factors.

Cortisol and Chronic Stress

Glucocorticoids, particularly cortisol, preferentially drive fat storage into visceral depots. Visceral adipocytes express more glucocorticoid receptors than subcutaneous adipocytes. Chronic psychological stress, sleep deprivation, or prolonged use of exogenous corticosteroids can accelerate VAT accumulation even without a large caloric surplus.

A 2018 meta-analysis in Psychoneuroendocrinology (N=21 studies) found that higher chronic cortisol exposure, as measured by hair cortisol concentrations, was consistently associated with greater VAT area across age groups. [5]

Sex Hormones and Age-Related Changes

Testosterone deficiency in men shifts fat distribution toward visceral depots. Hypogonadism is associated with visceral obesity, and testosterone replacement therapy (TRT) in hypogonadal men has been shown to reduce VAT in randomized trials. A 2016 meta-analysis in European Journal of Endocrinology (12 RCTs, N=1,083) reported that TRT reduced waist circumference by a mean of 2.6 cm and total body fat by 1.6 kg compared with placebo. [6]

In women, the transition through menopause produces a shift from gluteal-femoral fat storage to abdominal visceral storage as estrogen levels fall. Menopausal hormone therapy (MHT) may attenuate this shift. The KEEPS trial (N=727) observed that oral conjugated equine estrogen and transdermal estradiol both reduced total abdominal fat at 48 months compared with placebo, though the effect size differed by route. [7]

Genetics and Ethnicity

Fat distribution has a strong genetic component. South Asian, East Asian, and Hispanic populations tend to accumulate higher VAT area at equivalent BMI compared with White European populations. This is why waist-circumference cutoffs in IDF guidelines are lower for South Asian adults (90 cm for men, 80 cm for women) than for European adults. [3]

Health Risks Linked to High Visceral Fat

Excess visceral fat is not simply cosmetic. The downstream metabolic consequences are well-documented across large prospective cohorts.

Insulin Resistance and Type 2 Diabetes

Free fatty acids released from visceral fat into the portal circulation impair hepatic insulin signaling, reducing the liver's ability to suppress glucose production. This is one mechanism by which visceral adiposity drives fasting hyperglycemia even before clinical type 2 diabetes develops.

The Framingham Heart Study Offspring Cohort (N=3,001) found that each 1-standard-deviation increase in visceral fat area was associated with a 54% increase in the odds of incident type 2 diabetes over 7 years, after adjusting for total body fat. [8]

Cardiovascular Disease

Visceral fat is independently associated with hypertension, dyslipidemia, and elevated hsCRP. Elevated VAT area predicts coronary artery calcification scores independent of BMI and waist circumference.

Non-Alcoholic Fatty Liver Disease

NAFLD affects roughly 25% of the global adult population according to a 2016 meta-analysis in the Journal of Hepatology (N=8,515,431 individuals across 22 countries). [9] Visceral fat is the primary driver of hepatic fat deposition, and reducing VAT through weight loss consistently reduces liver fat content and liver enzyme elevations.

How to Reduce Visceral Fat

Visceral fat is responsive to lifestyle and pharmacological intervention. It tends to be the first depot mobilized during a caloric deficit, which is clinically encouraging.

Diet and Caloric Deficit

A sustained caloric deficit is the single most effective tool. Research consistently shows that visceral fat declines proportionally more than subcutaneous fat during weight loss. A 2012 randomized trial in Obesity (N=196) found that participants who lost 5% to 10% of body weight reduced VAT area by approximately 17% to 21%, which was disproportionate to total fat loss. [10]

No single dietary pattern has proven clearly superior for visceral fat specifically. Mediterranean, low-carbohydrate, and DASH diets all reduce VAT when they produce a meaningful caloric deficit. The key variable is the deficit, not the macronutrient ratio.

Aerobic Exercise

Aerobic exercise reduces visceral fat even without weight loss, which is a notable finding. A 2013 meta-analysis in PLOS ONE (30 randomized trials, N=2,326) found that aerobic exercise reduced VAT area by a mean of 6.1 cm² compared with no-exercise controls, independent of body weight change. [11] The authors noted that 150 to 180 minutes of moderate-intensity aerobic activity per week produced the largest effects.

Resistance Training

Resistance training preserves lean mass during a caloric deficit, which helps sustain metabolic rate. Its direct effect on visceral fat is smaller than aerobic exercise, but combining resistance training with aerobic exercise produces additive benefits for body composition.

GLP-1 Receptor Agonists

GLP-1 receptor agonists have emerged as the most effective pharmacological tools for reducing visceral fat in people with or without type 2 diabetes.

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% in the placebo group (P<0.001). [12] Body-composition sub-studies of STEP trials confirmed that the majority of weight lost on semaglutide was fat mass, with visceral and liver fat showing the greatest proportional reductions.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced even larger effects. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg achieved 20.9% mean weight loss at 72 weeks versus 3.1% with placebo. [13] A SURMOUNT body-composition sub-study found that approximately 67% of weight lost was fat mass, with visceral adipose tissue declining by roughly 40% of total fat reduction.

As stated in the 2023 American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines: "GLP-1 receptor agonists and dual agonists represent a new standard of care for adiposity-based chronic disease when lifestyle modification alone is insufficient." [14]

Testosterone Replacement Therapy in Hypogonadal Men

For men with confirmed hypogonadism (morning serum testosterone below 300 ng/dL on two separate measurements), TRT may reduce visceral fat as a secondary benefit beyond symptom management. The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy states: "We suggest that clinicians consider testosterone therapy in men with hypogonadism who have metabolic syndrome or type 2 diabetes, as testosterone may improve body composition and insulin sensitivity." [15]

Menopausal Hormone Therapy in Women

For perimenopausal and postmenopausal women experiencing rapid visceral fat gain, MHT may help attenuate the redistribution of fat from peripheral to central depots. The decision to use MHT must account for each patient's cardiovascular risk profile, breast cancer history, and individual symptom burden, consistent with the 2022 Menopause Society (NAMS) Position Statement on hormone therapy. [16]

How Visceral Fat Relates to Metabolic Syndrome

Metabolic syndrome is defined by any three of five criteria: elevated waist circumference, elevated fasting triglycerides, reduced HDL-cholesterol, elevated blood pressure, and elevated fasting glucose. Visceral fat excess is the central mechanism linking these five criteria together.

The NCEP ATP III definition, updated in 2005 and still used in clinical practice, sets the waist circumference threshold at 40 inches (102 cm) for men and 35 inches (88 cm) for women in the U.S. Population. Reaching this threshold alone puts a person at elevated risk for all remaining four criteria appearing over time.

Reducing VAT by even 10% to 15% often produces measurable improvements across multiple metabolic syndrome components simultaneously. A 2011 study in Diabetes Care (N=332) reported that a 10% reduction in VAT area correlated with a 22% reduction in fasting triglycerides, a 3 mmHg reduction in systolic blood pressure, and a 0.3 mmol/L reduction in fasting glucose over 12 months of supervised lifestyle intervention. [17]

Monitoring Visceral Fat Over Time

Because visceral fat is not directly visible, tracking progress requires either serial measurements or validated proxies.

Waist circumference measured consistently at the same anatomical landmark (the midpoint between the lowest rib and the iliac crest, per WHO protocol) is the most practical home-monitoring approach. A reduction of 4 to 6 cm in waist circumference over 6 months generally reflects a clinically meaningful decrease in VAT area.

For patients enrolled in structured programs, a repeat DEXA scan at 6 months provides objective documentation of fat-mass changes, including VAT. Pair this with fasting lipids, fasting glucose, and blood pressure to assess the full metabolic response.

Body-composition scales using bioelectrical impedance can track directional trends, but measure under consistent conditions: in the morning, before eating, after using the bathroom, without clothes. Hydration status strongly affects the reading, so a single number carries less meaning than a 4-to-8-week average.